42 results about "Targeted immunotherapy" patented technology

The invention provides an immunotherapy reaction marker identification method and system based on a cooperative game theory, and relates to the technical field of intelligent medical treatment, and the method comprises the following steps: obtaining immunotherapy single cell sequencing data, and determining a candidate gene set through differential expression analysis; extracting regulation and control relation pairs of the candidate gene set to obtain a multi-level information gene regulation and control network; embedding the multilevel information gene regulation and control network by adopting a Node2vec algorithm to obtain a network module containing potential biological functions, calculating the contribution degree of each gene feature to model prediction based on a Myerson value, and obtaining a feature importance sequence; combining the optimal features of the modules into a global candidate set; and iteratively optimizing the global candidate set, and outputting a target immunotherapy reaction marker set. Through a Myerson value principle in a cooperative game, a biomarker set related to immunotherapy response is efficiently searched, deep analysis of a drug resistance mechanism is realized, the accuracy and robustness of marker screening are improved, and the method serves for cancer clinical scheme customization.

The invention discloses a folic acid-polylactic acid double-layer vesicle delivery system for targeting MDSC cells in a focus and a preparation method and application of the folic acid-polylactic acid double-layer vesicle delivery system, the folic acid-polylactic acid double-layer vesicle delivery system comprises an inner-layer vesicle and an outer-layer vesicle, and a contrast agent is contained between the inner-layer vesicle and the outer-layer vesicle; the inner-layer vesicle is formed by self-assembling two block polymers, the outer wall of the inner-layer vesicle is positively charged, the inner-layer vesicle is compounded with an immunoregulation therapeutic gene through electrostatic interaction, the surface of the inner-layer vesicle is modified by an antibody targeting an MDSC cell surface marker, and a therapeutic drug is loaded in the inner-layer vesicle; the outer vesicle is formed by a liposome modified by targeted disintegration enzyme substrate polypeptide-PEG (Polyethylene Glycol). According to the double-layer vesicle delivery system, the delivery regulation range of the COX-2 inhibitor and folic acid targeted immunotherapy can be limited to local lesion placenta, the toxicity of immune drugs to pregnant women is effectively reduced, effective immunotherapy of placental diseases is made possible, the current situation that no treatment means are provided for placental dysfunction diseases is remarkably improved, and the application prospect is wide. A new thought is provided for effective immunotherapy of placenta dysfunction diseases.

The invention relates to the technical field of biological medicines, particularly discloses an application of a CCR5hi innate immune memory cell in preparation of an immunotherapy drug for treating sepsis, and provides an innate immune memory cell CD45 + CD11b + Ly6G-Ly6C + CCR5hi mononuclear cell which is generated by induction training immunity of bacillus calmette guerin vaccine and bacterial lipoprotein and has a protection effect on sepsis. Through single cell sequencing analysis and functional verification, the cell subset characteristics of the sepsis are accurately identified, and the functional mechanism of the sepsis is clarified, so that the key blank of unclear effector cell identity and unclear action target in the prior art is filled, and a cellular theoretical basis and a technical scheme are provided for targeted immunotherapy of the sepsis; and a better treatment effect is expected to be achieved in clinical practice.

The invention discloses a PD-1 (programmed death-1) and PD-L1 (programmed death-L1) gene polymorphism detection kit and a use method thereof. The kit is used for detecting an rs34819629 site of a PD-1 gene and an rs2297137 site of a PD-L1 gene, four groups of primer sequences are designed, and the kit further comprises a PCR (Polymerase Chain Reaction) reaction buffer solution, dNTPs (Deoxyribose Nucleic Acid), DNA (Deoxyribonucleic Acid) polymerase and template DNA. The kit disclosed by the invention is an efficient tool for detecting the specific polymorphism of the PD-1 and PD-L1 genes, and has the characteristics of high accuracy, simplicity in operation and capability of supporting personalized medical treatment. Through the detection kit, targeted immunotherapy suggestions can be provided for patients, the effectiveness of immunotherapy is remarkably improved, important gene information is provided for related researches, and development of diabetes immunotherapy is promoted.

To provide improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.SOLUTION: Provided are VHH-based dimerizing agent regulated immunoreceptor complexes (DARICs) and VHH-based chimeric antigen receptors (CARs) directed against CLL-1, polynucleotides encoding the same, compositions thereof, and methods of making and using the same to treat cancer.SELECTED DRAWING: Figure 1A

The invention provides an application of an ANXA1 protein or an antagonist thereof in preparation of a medicine for treating multiple myeloma. After the multiple myeloma BCMA immunotherapy, when BCMA negative recurrence occurs, in multiple myeloma cells, a BCMA receptor signal channel is reduced, ANXA1 protein expression quantity is increased, proliferation of the multiple myeloma cells is promoted, and CAR-T cell immunocompetence and immune persistence are inhibited at the same time. The antagonist of the ANXA1 protein reduces the expression quantity of the ANXA1 protein, inhibits the proliferation of multiple myeloma cells, and recovers the immunocompetence and immune persistence of CAR-T cells at the same time. According to the application, the biological function of the ANXA1 in the MM cells is defined, the action mechanism of the ANXA1 antagonist for treating the BCMA negative MM cells and improving the activity of the CAR-T cells is proved, a valuable theoretical basis is provided for improvement of clinical myeloma CAR-T cell treatment, and finally the disease-free lifetime of a patient after BCMA-targeted immunotherapy is prolonged.

Methods and compounds for conferring kidney-glomerular-specific immunotherapy.

Provided herein are compositions, systems, and methods for producing small extracellular vesicles (sEVs) that are mRNA-loaded and include CD64 on the sEV surface. Also provided are the immunogenic EVs (imsEVs) that further include a targeting ligand bound to the CD64 on the imsEV surface. The disclosure also provides fusion proteins including a CD64 amino acid sequence fused to an N peptide amino acid sequence. Also provided are nucleic acids that encode the fusion proteins, and vectors and cells that comprise the nucleic acids. Also disclosed are methods for using the imsEVs for immunotherapy, such as for the treatment of cancer in a subject.

The invention discloses a prediction model for predicting a liver cancer combined treatment effect based on multi-mode MRI radiomics characteristics and a construction method and application thereof, and belongs to the technical field of liver cancer treatment effect prediction. In order to solve the problem that only part of liver cancer patients can benefit from an arterial chemoembolization combined targeted immunotherapy scheme at present, the invention proposes that before combined therapy, MRI radiomics characteristics and clinical factors are enhanced through noninvasive multi-modal comparison, multiple machine learning models are established, and the model learning model is used for learning the liver cancer patients. The tumor treatment response of arterial chemoembolism combined with molecular targeting and immunotherapy is predicted, and the applicability of the radiomics model is verified by using an external data set; besides, the radiomics model is combined with a clinical model, so that the method has more excellent prediction efficiency, and the radiomics features provide incremental prediction value for clinical factors. According to the method, the combined treatment effect of the liver cancer patients can be predicted, so that more effective and reasonable treatment schemes can be selected for different patients before treatment.

The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Among the various aspects of the present disclosure is the provision of methods of detecting and treating immunotherapy-resistant B cell malignancies. Methods of detection include detecting a glycosylation state of CD19 or detecting expression or activity of SPPL3 in malignant B cells, comparing to a reference state or value, and determining that the B cell malignancy is resistant to immunotherapy if the glycosylation state of CD19 or expression or activity of SPPL3 is substantially increased or decreased relative to corresponding reference levels. Also provided are therapeutic agents capable of modulating CD19 glycosylation or SPPL3 expression or activity for treatment of B cell malignancies in combination with CD19-targeted immunotherapies.

Provided are novel human-derived antibodies specific for transthyrelin (TTR), preferably capable of binding misfolded, misassembled, and / or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and / or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to anti-bodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.

This invention belongs to the field of biomedical technology, specifically disclosing the application of cimicifuga in the preparation of drugs for treating periodontitis. Specifically, it relates to the application of cimicifuga in the preparation of drugs for treating periodontitis; and the application of cimicifuga in the preparation of drugs for treating alveolar bone defects (periodontal bone defects) caused by periodontitis. It also relates to the application of cimicifuga in the preparation of products for inhibiting macrophage polarization towards M1 and / or promoting macrophage polarization towards M2 in a single macrophage system. In this disclosure, cimicifuga has no significant toxicity to macrophages and has high safety; it targets and regulates macrophage polarization, inhibiting periodontal inflammation at its source; it significantly reduces inflammatory infiltration and osteoclast formation in periodontal tissues, effectively alleviating alveolar bone defects; and it provides a novel targeted immunotherapy drug for periodontitis, expanding the clinical application of single traditional Chinese medicine monomers.

Relapsed / refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. CD1a is exclusively expressed in cortical T-ALLs, a major subset of T-ALL. The expression of CD1a is restricted to cortical thymocytes and neither CD34+ progenitors nor T-cells express CD1a during ontogeny, confining the risk of on-target / off-tumor toxicity. The present invention provides CD1a-targeting moieties comprising a CD1a-which may be placed into T cells. The resultant CARTs are suitable for the treatment of cortical T-ALLs.

Embodiments of the present disclosure pertain generally to head and neck squamous cell carcinomas (HNSCCs) related to human papillomavirus subtype 16 (HPV16) infections. More particularly, the present disclosure provides novel immunogenic epitopes from HPV16 E2, E6 and E7 antigens restricted by common human leukocyte antigen (HLA) alleles for the diagnosis and treatment of HNSCC. The HPV16 epitopes identified in the present disclosure can be used in combination with blockade of HPV16+ HNSCC-specific checkpoints for targeted immunotherapy.

Embodiments of the present disclosure pertain generally to head and neck squamous cell carcinomas (HNSCCs) related to human papillomavirus subtype 16 (HPV16) infections. More particularly, the present disclosure provides novel immunogenic epitopes from HPV16 E2, E6 and E7 antigens restricted by common human leukocyte antigen (HLA) alleles for the diagnosis and treatment of HNSCC. The HPV16 epitopes identified in the present disclosure can be used in combination with blockade of HPV16+ HNSCC-specific checkpoints for targeted immunotherapy.

The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapy for treating, preventing or ameliorating at least one symptom or a condition associated therewith of cancer, infectious diseases, autoimmune diseases, inflammatory diseases and immune deficiencies.

Provided are novel human-derived anti-huntingtin (HTT) antibodies and biotechnological derivatives thereof, preferably capable of binding mutated and / or aggregated HTT species and or fragments thereof, as well as methods related thereto. The human-derived anti-HTT antibodies and biotechnological derivatives can be used in pharmaceutical and diagnostic compositions for HTT targeted immunotherapy of Huntington Disease and diagnosis thereof.

The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present disclosure provides a virus like particle comprising a viral structural protein and a galectin epitope peptide, and a composition or vaccine comprising thereof, its use in a medicine, particularly in an immunotherapy.

The invention discloses a chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation as well as a preparation method and application of the chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation. According to the nano preparation, outer membrane vesicles derived from fecal bacillus rodent are taken as a delivery carrier, and an anti-PD-L1 antibody is stably coupled to the surfaces of the vesicles under the chemical cross-linking action of DSPE-PEG-NHS, so that the composite nano preparation MVs / alpha-PD-L1 is formed; in-vitro experiments show that the composite nano preparation can significantly inhibit the activity of breast cancer cells and induce apoptosis of the breast cancer cells; in a 4T1 in-situ breast cancer mouse model, tumor growth can be effectively inhibited, a tumor immune microenvironment can be remodeled, the biological safety is good, and a safe and effective novel delivery system is provided for targeted immunotherapy of breast cancer.

Relapsed / refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. The extension of chimeric antigen receptor T-cells (CARTs) to T-ALL remains challenging because the shared expression of target antigens between CARTs and T-ALL blasts leads to CARTs fratricide. CD 1a is exclusively expressed in cortical T-ALLs, a major subset of T-ALL. The expression of CD 1a is restricted to cortical thymocytes and neither CD34+ progenitors nor T-cells express CD 1a during ontogeny, confining the risk of on-target / off-tumor toxicity. The present invention provides CARs comprising a CD 1a-targeting moiety which may be transduced or transformed into T cells. The resultant CARTs are suitable for the treatment of cortical T-ALLs.

Provided are novel human-derived monoclonal neutralizing Nogo-A specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Polynucleotides, vectors, host cells and kits related to the Nogo-A specific antibodies are also provided. The antibodies, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for Nogo-A targeted immunotherapy and diagnosis, respectively.

The present disclosure provides a method for treating an eligible subject with acute myeloid leukemia including high-risk disease features comprising administering to the subject post-consolidation a targeted immunotherapy comprising an immunotherapeutic agent specifically targeting B cell maturation antigen.

Provided are novel human-derived antibodies specific for transthyretin (TTR), preferably capable of binding misfolded, misassembled, and / or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and / or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to antibodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.

Provided are novel human-derived antibodies specific for transthyrelin (TTR), preferably capable of binding misfolded, misassembled, and / or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and / or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to anti-bodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.

Recurrent / refractory T cell acute lymphoblastic leukemia (T-ALL) has the outcome of depression, and there is no effective targeted immunotherapy against T-ALL. The CD1a is only expressed in one main subclass of the T-ALL and in the cortex T-ALL. Expression of CD1a is limited to that neither cortical thymus cells nor CD34 + progenitor cells nor T cells express CD1a in the individual development process, and therefore the risk of targeted / non-tumor toxicity is limited. The present invention provides a CD1a targeting moiety comprising CD1a, which can be placed in a T cell. The CART thus generated is suitable for the treatment of cortex T-ALL.

The invention provides application of luteolin in enhancement of lung cancer targeted immunotherapy, relates to the technical field of biological medicine, and relates to combined application of traditional Chinese medicine monomer luteolin and an immunotherapy preparation of a targeted immune checkpoint B7-H3 in treatment of non-small cell lung cancer (NSCLC). The immunotherapeutic agent is preferably a bispecific killer cell adapter (BiKE) that targets both B7-H3 and CD16. In-vitro cell experiments and in-vivo animal models prove that luteolin can significantly enhance the killing effect of the B7-H3 targeted immunotherapy on NSCLC cells, and the luteolin and the B7-H3 targeted immunotherapy show a significant synergistic anti-tumor effect. The action mechanism of the luteolin is possibly related to the luteolin for inducing cell apoptosis, improving the level of reactive oxygen species (ROS) in cells and inhibiting a PI3K / AKT signal channel. The combined strategy provides a new effective scheme for solving the problems of limited curative effect and drug resistance of NSCLC immunotherapy, and has a good clinical application prospect.

The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory discase, and immunodeficiency, or condition associated therewith.